← Leaderboards
Ya-Chen Tina Shih
University Of Tx Md Anderson Can Ctr
$6,381,441
Attributed
$7,827,867
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2007–23$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,452,793 · 6
AHRQ$1,375,074 · 1
By mechanism
R01$6,556,114 · 4
RC1$722,753 · 1
R21$395,000 · 1
R03$154,000 · 1
Top collaborators
- Liang Li5 shared
- Lovell Allan Jones3 shared
- Yu Shen2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Scott Kopetz$13,199,822
- Holly M. Holmes$786,874
- Beverly A Guadagnolo$347,453
- Cathy Eng$2,834,277
- Sattva S Neelapu$3,334,171
Others in their field
Top investigators on “Cost”
- Eric S Lander · Whitehead Institute For Biomedical Res$748,368,930
- Richard K. Wilson · Washington University$429,230,873
- Richard A Gibbs · Baylor College Of Medicine$414,258,216
- David R. Weir · University Of Michigan At Ann Arbor$393,741,481
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
Research focus
CostMalignant NeoplasmsMedicarePolicy MakerDatabasesPoliciesPatternCancer CareCohortDiagnosisPharmaceutical PreparationsEconomicsCancer PatientBaseUnited StatesChemotherapyInnovationMultidisciplinaryEconomic ImpactMedical OncologyHealth Services ResearchLifeExpenditureCare Costs
Grant awards (27)
Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors and Economic Implications$278,472
R01 · FY2023 · CA · contact PI
Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications$52,401
R01 · FY2023 · CA · contact PI
Estimating the Cost Trajectories and Projecting the Cost of Cancer Care in the United States: Methodology and Application$358,680
R01 · FY2022 · CA
Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications$349,924
R01 · FY2022 · CA · contact PI
Estimating the Cost Trajectories and Projecting the Cost of Cancer Care in the United States: Methodology and Application$366,000
R01 · FY2021 · CA
Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications$338,009
R01 · FY2021 · CA · contact PI
Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications$404,592
R01 · FY2020 · CA · contact PI
Estimating the Cost Trajectories and Projecting the Cost of Cancer Care in the United States: Methodology and Application$366,000
R01 · FY2020 · CA
Technology Diffusion in Cancer: Geographic Variations, Facilitators, Outcomes, and Costs$273,604
R01 · FY2020 · CA · contact PI
Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications$407,421
R01 · FY2019 · CA · contact PI
Technology Diffusion in Cancer: Geographic Variations, Facilitators, Outcomes, and Costs$394,825
R01 · FY2019 · CA · contact PI
Estimating the Cost Trajectories and Projecting the Cost of Cancer Care in the United States: Methodology and Application$355,019
R01 · FY2019 · CA
Estimating the Cost Trajectories and Projecting the Cost of Cancer Care in the United States: Methodology and Application$329,400
R01 · FY2018 · CA
Technology Diffusion in Cancer: Geographic Variations, Facilitators, Outcomes, and Costs$273,604
R01 · FY2018 · CA · contact PI
Technology Diffusion in Cancer: Geographic Variations, Facilitators, Outcomes, and Costs$273,604
R01 · FY2017 · CA · contact PI
Technology Diffusion in Cancer: Geographic Variations, Facilitators, Outcomes, and Costs$359,485
R01 · FY2016 · CA · contact PI
Monoclonal Antibodies in Cancer Care: Is Underinsurance An Access Barrier?$291,856
R01 · FY2012 · HS · contact PI
Technology Diffusion & Cost-Effectiveness of Mammography Screening in Older Women$197,500
R21 · FY2012 · CA
Monoclonal Antibodies in Cancer Care: Is Underinsurance An Access Barrier?$328,439
R01 · FY2011 · HS · contact PI
Technology Diffusion & Cost-Effectiveness of Mammography Screening in Older Women$197,500
R21 · FY2011 · CA
A Comprehensive Model to Assess the Cost-Effectiveness of Patient Navigation$337,850
RC1 · FY2010 · CA · contact PI
Monoclonal Antibodies in Cancer Care: Is Underinsurance An Access Barrier?$298,584
R01 · FY2010 · HS · contact PI
A Comprehensive Model to Assess the Cost-Effectiveness of Patient Navigation$27,435
RC1 · FY2010 · CA · contact PI
Monoclonal Antibodies in Cancer Care: Is Underinsurance An Access Barrier?$456,195
R01 · FY2009 · HS · contact PI
A Comprehensive Model to Assess the Cost-Effectiveness of Patient Navigation$357,468
RC1 · FY2009 · CA · contact PI
Economic Evaluations of Emerging Genomic Tests for Early Stage Breast Cancer$77,000
R03 · FY2008 · HG · contact PI
Economic Evaluations of Emerging Genomic Tests for Early Stage Breast Cancer$77,000
R03 · FY2007 · HG · contact PI